Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
Status:
Recruiting
Trial end date:
2022-03-03
Target enrollment:
Participant gender:
Summary
Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap
between their types, with cardiac problems being among the most commonly observed
manifestations and are also among the main causes of mortality in these patients. For some of
the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is
no effective treatment currently available. Losartan, on the other hand, has been shown to be
an effective drug for dilation of the aortic root, at least in animal models. This study aims
to evaluate the safety and efficacy of losartan in patients with MPS VI and other
mucopolysaccharidoses.